NYSE
$1.15▲ 0.44%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $69.9MShares out 60.8M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
18- 10.7Pre-market26.10.07 19:08424B3Offering#●●●#●●●#●●●
MAIA Biotechnology, Inc.
MAIA Biotechnology has registered 751,879 shares of common stock for resale by a selling stockholder pursuant to a clinical trial funding agreement. While the company will not receive proceeds from this specific share sale, the selling stockholder has agreed to provide $1,000,000 in funding for the company's clinical studies. These shares are freely tradable upon registration and may result in dilution for existing shareholders.…more
$1.15+0.44%vs prev closeView filingShare
- 10.7Pre-market26.10.07 13:15filedEFFECTOther
MAIA Biotechnology, Inc.
MAIA Biotechnology's registration statement was declared effective by the SEC on October 6, 2026. This approval allows the company to proceed with the offering and sale of the securities described in the filing.…more
$1.15+0.44%vs prev closeView filingShare - 10.6Pre-market26.10.06 21:158-KKey event
MAIA Biotechnology, Inc.
MAIA Biotechnology posted a new presentation and summary regarding its operations and performance on its website on October 6, 2026. These materials were prepared for management to use in future investor presentations and have been disclosed via this filing.…more
$1.15+0.44%vs prev closeView filingShare
17 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.7Pre-market26.10.07 21:16#●●●#●●●
MAIA Biotechnology Completes Patient Enrollment for Phase 2 NSCLC Trial…more
MAIA Biotechnology has completed patient enrollment for Part C of its Phase 2 clinical trial evaluating ateganosine in combination with cemiplimab for non-small cell lung cancer. The company reported promising interim disease control rates, significantly outperforming standard chemotherapy outcomes.…more
$1.15+0.44%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.25After-hours26.09.26 06:09
●●●●●●●● ●●●●● ●●●●●●
MAIA Biotechnology has filed a prospectus for the resale of 751,879 shares issued under a clinical trial funding agreement. The company will not receive any proceeds from these share sales.…more
$1.15+0.44%vs prev closeShareBenzinga - 9.23Pre-market26.09.23 22:17
●●●●●●●● ●●●●● ●●●●●●
MAIA Biotechnology is expanding its pivotal Phase 3 clinical trial for the lung cancer drug THIO-104 into Spain and Portugal. The company remains on track to conduct an interim survival analysis in 2027.…more
$1.15+0.44%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report